Subject: Immune Response In Talks on Vaccine For Treating HIV
Date: Published: 2/10/92 (39 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Technology:
    Immune Response
    In Talks on Vaccine
    For Treating HIV

    SAN DIEGO -- Immune Response Corp. said it and two large
 drug concerns have begun discussions about forming a joint
 venture to manufacture Immune Response's vaccine for the
 treatment of HIV infection, which causes AIDS.  
    The other firms are Rhone-Poulenc Rorer Inc., an
 international pharmaceutical company, and the Pasteur Merieux
 Connaught Group, a large vaccine manufacturer and a
 subsidiary of Institut Merieux and Rhone-Poulenc S. A. 
    Immune Response is a biopharmaceutical concern engaged in
 developing products for treatment of HIV infection and such
 other autoimmune diseases as rheumatoid arthritis.
    Immunization Products Ltd., a joint venture between Immune
 Response and Rhone-Poulenc Rorer, is conducting clinical
 trials of the HIV therapeutic vaccine on humans in the U. S. 
 The trials are scheduled to be completed later this year.  The
 Primary objective is to support a product license application
 for 1993 and to secure Food and Drug Administration approval
 for commerical marketeting of the HIV vaccine, Immuine
 Response said.
    The Immune Response vaccine is based on a scientific
 approach first suggested by Dr. Jonas Salk, a founder of
 Immune Response and developer of the Salk polio vaccine.  Dr. 
 Salk proposed using whole but inactivated AIDS viruses to
 inoculate people already infected.  Where other researchers
 use genetically engineered or synthetic virus proteins, Dr. 
 Salk chose to use live viruses killed with gamma radiation.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]